行情

INMB

INMB

INMUNE BIO, INC.
NASDAQ

实时行情|Nasdaq Last Sale

5.60
-0.06
-1.06%
已收盘, 16:00 01/21 EST
开盘
5.58
昨收
5.66
最高
5.62
最低
5.52
成交量
1.20万
成交额
--
52周最高
11.50
52周最低
3.505
市值
6,031.73万
市盈率(TTM)
-7.7875
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INMB 新闻

  • Investor Presentation - January 2020
  • Seeking Alpha - Article.01/13 02:29
  • INmune Bio up 4% on potential of lead candidate in Alzheimer's
  • Seeking Alpha - Article.01/02 15:46
  • INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals
  • GlobeNewswire.01/02 14:00
  • Benzinga's Top Upgrades, Downgrades For December 19, 2019
  • Benzinga.2019/12/19 14:51

更多

所属板块

生物技术和医学研究
-0.74%
制药与医学研究
-0.40%

热门股票

名称
价格
涨跌幅

INMB 简况

Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).
展开

Webull提供INmune Bio Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。